Stockscreener 앱 받기
158.01
1.29%
2.01
시간 외 거래:
159.91
1.90
+1.20%
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen (NASDAQ:BIIB) Given New $207.00 Price Target at Mizuho - MarketBeat
Primecap Management Co. CA Sells 23,215 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Unusual Options Activity For November 20 - Benzinga
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Yahoo Finance
ANCA Vasculitis Pipeline Trends 2024: Clinical Trials, - openPR
Biogen ‘welcomes’ EC decision to revoke CMAs for generic versions of Tecfidera - MSN
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More - BioSpace
(BIIB) Pivots Trading Plans and Risk Controls - Stock Traders Daily
European committee takes a second look at Alzheimer's drug and now says it should be approved - MSN
Biogen at the 7th Annual Evercore HealthCONx Conference - Biogen | Investor Relations
Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Biogen to Participate in the 7th Annual Evercore HealthCONx Conference - Biogen | Investor Relations
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab - MSN
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eyes Second Phase III - BioSpace
Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation - PMLiVE
Thrivent Financial for Lutherans Reduces Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
UCB: positive phase 3 results in lupus - Marketscreener.com
Empowered Funds LLC Has $3.67 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen: positive phase 3 results in lupus - Marketscreener.com
BIIBBiogen Inc. Latest Stock News & Market Updates - StockTitan
Biogen/UCB’s Lupus Drug Shows Consistent Efficacy Across Endpoints, Over Time - Citeline News & Insights
Dapirolizumab Pegol Phase 3 Data Presented at the American - GlobeNewswire
Biogen's Lupus Drug Shows 49.5% Response Rate in Phase 3 Trial, Beats Standard Care | BIIB Stock News - StockTitan
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 - Yahoo Finance
Needham downgrades Biogen on slow growth of Alzheimer's drug By Investing.com - Investing.com Canada
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales (NASDAQ:BIIB) - Seeking Alpha
Needham downgrades Biogen on slow growth of Alzheimer's drug - Investing.com
Opuviz is latest EC-approved ophthalmology biosimilar - The Pharma Letter
Biogen (NASDAQ:BIIB) Sets New 12-Month LowShould You Sell? - MarketBeat
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ - Biogen | Investor Relations
Biogen (NASDAQ:BIIB) Downgraded to "Hold" Rating by Needham & Company LLC - MarketBeat
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ - GlobeNewswire
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ - GlobeNewswire Inc.
Analyst recommendations: Biogen, HP, Moderna, Shell... - Marketscreener.com
KBC Group NV Has $6.44 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? - Insider Monkey
Top 10 Alzheimer’s Disease Therapeutics Companies | Provides Best TreatmentsMarket.us Media - Market.us Media - United States Market News
Seizert Capital Partners LLC Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Mizuho Securities USA LLC Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
ING Groep NV Has $3.81 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Impax Asset Management Group plc Has $7.52 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Los Angeles Capital Management LLC Purchases Shares of 4,282 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
How a Biogen drug set the stage for a new biotech targeting ALS - BioPharma Dive
BIIB (Biogen) Total Inventories : $2,469 Mil (As of Sep. 2024) - GuruFocus.com
Biogen Unusual Options Activity - Benzinga
Cornercap Investment Counsel Inc. Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe - Yahoo Finance
Biogen (NASDAQ:BIIB) Now Covered by Analysts at Wolfe Research - MarketBeat
Citigroup Upgrades Biogen (NASDAQ:BIIB) to Hold - MarketBeat
Prime Capital Investment Advisors LLC Sells 5,201 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $71.75 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment) - ACN Newswire
European Agency Switches to Recommending New Alzheimer's Drug - Nippon.com
Eisai wins over European regulators on Alzheimer’s drug Leqembi - BioPharma Dive
Leqembi, which was developed by US multinational Biogen and Japanese-based Eisai, is the brand name of an active substance called lecanemab that is used to treat adults with mild memory and cognitive problems resulting from the early stages of the com - Islander News.com
EU regulator backs Eisai-Biogen Alzheimer’s drug - The Hindu
NATIONWIDE TV COMMERCIAL LAUNCHED IN JAPAN TO RAISE AWARENESS ABOUT MCI (MILD COGNITIVE IMPAIRMENT) - Eisai
Biogen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall - Boston Herald
Leqembi Secures EMA Thumbs Up For Narrower Indication - Citeline News & Insights
0.60%
자본화:
|
볼륨(24시간):